Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
10.57
+0.32 (3.12%)
Nov 6, 2026, 4:00 PM EST - Market closed
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 173 employees as of June 30, 2026. The number of employees increased by 31 or 21.83% compared to the same quarter last year. That makes Monte Rosa Therapeutics the 27,854th largest employer in the world and 3,513th in the United States.
Employees
173
Change (1Y)
31
Growth (1Y)
21.83%
Revenue / Employee
$406,503
Profits / Employee
-$757,064
Market Cap
901.76M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 173 | 31 | 21.83% |
| Mar 31, 2026 | 161 | 19 | 13.38% |
| Dec 31, 2025 | 150 | 16 | 11.94% |
| Sep 30, 2025 | 147 | 14 | 10.53% |
| Jun 30, 2025 | 142 | 13 | 10.08% |
| Mar 31, 2025 | 142 | 12 | 9.23% |
| Dec 31, 2024 | 134 | 1 | 0.75% |
| Sep 30, 2024 | 133 | 0 | - |
| Jun 30, 2024 | 129 | -4 | -3.01% |
| Mar 31, 2024 | 130 | -3 | -2.26% |
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Sep 30, 2023 | 133 | 15 | 12.71% |
| Jun 30, 2023 | 133 | 29 | 27.88% |
| Mar 31, 2023 | 133 | 38 | 40.00% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Sep 30, 2022 | 118 | 24 | 25.53% |
| Jun 30, 2022 | 104 | 21 | 25.30% |
| Mar 31, 2022 | 95 | 35 | 58.33% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| Pharming Group | 407 |
| MeiraGTx Holdings | 393 |
| Syndax Pharmaceuticals | 298 |
| ORIC Pharmaceuticals | 111 |
| Odyssey Therapeutics | 100 |
| Inventiva | 87 |
| Corvus Pharmaceuticals | 37 |
GLUE News
- 1 day ago - Monte Rosa Therapeutics price target lowered to $15 from $25 at Jefferies - TheFly
- 1 day ago - Monte Rosa Therapeutics reports Q3 revenue $54.37M, consensus $33.89M - TheFly
- 1 day ago - Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - GlobeNewsWire
- 1 day ago - Monte Rosa Therapeutics Quarterly report: Q3 2026 - Filings
- 1 day ago - Monte Rosa Therapeutics Earnings release: Q3 2026 - Filings
- 3 days ago - Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 9 days ago - Monte Rosa Therapeutics collaborator Novartis initiates MGD MRT-6160 study - TheFly